TriLink BioTechnologies® collaborates with Avantor® to enhance nucleic acid solutions in Europe.
Monday, February 03, 2025
TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company, has formed a partnership with Avantor, Inc. to expand the availability of its nucleic acid products across Europe, the Middle East, and Africa (EMEA). This collaboration aims to streamline the ordering process, reduce lead times, and improve access to TriLink’s nucleic acid technologies for customers in the region.
With over 25 years of experience in nucleic acid product development and manufacturing, TriLink is recognised as a leading provider of mRNA-based therapeutic innovations. Under this agreement, its products, including CleanCap® cap analogs, catalog mRNAs, more than 150 modified and unmodified nucleotides, and high-performance IVT enzymes such as CleanScribe® RNA Polymerase, will be more widely available in EMEA. These products can be used for research purposes or produced at GMP-grade. In addition, TriLink’s offerings will soon be accessible through VWR’s eCommerce platform, MarketSource.
TriLink continues to support the development of nucleic acid therapeutics, vaccines, and diagnostics by providing advanced technology, specialised chemistry, and Contract Development and Manufacturing Organization (CDMO) services. Its portfolio includes mRNA capping analogs, such as the award-winning CleanCap® M6, as well as raw materials like nucleotides and IVT enzymes, including wild-type T7 RNA polymerase. The company also offers scale-up capabilities and expertise in mRNA, oligonucleotide, and enzyme production.
Source: businesswire.com
